Inovalon (INOV) Tops Q4 EPS by 1c

Inovalon (NASDAQ: INOV) reported Q4 EPS of $0.15, $0.01 better than the analyst estimate of $0.14. Revenue for the quarter came in at $173.5 million versus the consensus estimate of $172.17 million.

For earnings history and earnings-related data on Inovalon (INOV) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recover